Institutional shares held 60.4 Million
1.6M calls
1.41M puts
Total value of holdings $6.15B
$163M calls
$143M puts
Market Cap $6.08B
59,719,600 Shares Out.
Institutional ownership 101.07%
# of Institutions 394


Latest Institutional Activity in BPMC

Top Purchases

Q1 2025
Universal Beteiligungs Und Servicegesellschaft Mb H Shares Held: 84.8K ($8.63M)
Q1 2025
Moody Aldrich Partners LLC Shares Held: 22.3K ($2.27M)
Q1 2025
Y Intercept (Hong Kong) LTD Shares Held: 21.5K ($2.19M)
Q1 2025
Royce & Associates LP Shares Held: 18K ($1.83M)
Q1 2025
Ami Asset Management Corp Shares Held: 11K ($1.12M)

Top Sells

Q1 2025
William Blair Investment Management, LLC Shares Held: 1.43M ($146M)
Q1 2025
Pictet Asset Management Holding Sa Shares Held: 955K ($97.2M)
Q1 2025
Vanguard Group Inc Shares Held: 6.64M ($676M)
Q1 2025
Goldman Sachs Group Inc Shares Held: 927K ($94.4M)
Q1 2025
Deutsche Bank Ag\ Shares Held: 200K ($20.4M)

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at BPMC

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
385K Shares
From 25 Insiders
Grant, award, or other acquisition 171K shares
Exercise of conversion of derivative security 214K shares
Sell / Disposition
381K Shares
From 12 Insiders
Open market or private sale 381K shares

Track Institutional and Insider Activities on BPMC

Follow Blueprint Medicines Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BPMC shares.

Notify only if
Any

Insider Trading

Get notified when an Blueprint Medicines Corp insider buys or sells BPMC shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Blueprint Medicines Corp

Track Activities on BPMC